| Aggression |
NCT02938741: ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors |
|
|
| Recruiting | 4 | 130 | RoW | Anti-human Thymoglobulin, (r-ATG ）, Placebo | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Lymphoblastic Lymphoma | 12/21 | 12/22 | | |
| Recruiting | 2 | 135 | Europe | R-DHAP/R-ICE, R-DHAP or R-ICE and BEAM or FEAM | Fondazione Italiana Linfomi ONLUS | Non Hodgkin Lymphoma | 12/18 | 02/23 | | |
NCT01898416: Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors |
|
|
| Recruiting | 2 | 140 | RoW | 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug. | michal roll | The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an, Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After, Surgical Resection | 12/23 | 12/26 | | |
NCT02955446: Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies |
|
|
| No Longer Available | N/A | | US | PF-03084014, Gamma Secretase Inhibitor | University of Colorado, Denver, SpringWorks Therapeutics, Inc. | Neoplasm, Desmoid Tumor | | | | |